LIVE
VEEV
Veeva Systems Inc. · Technology - Life Sciences Cloud
$153.30
-6.13% this month
VERSUS
⟷
COMPARE
MED
Medidata Solutions (Dassault Systèmes) · Technology - Clinical Trials Cloud
$11.04
-12.31% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
VEEV
2
MED
2
Comparison scoreboard
MIXED SETUPAI Score
VEEV ✓50.3
MED 23.8
1Y Return
VEEV -45.53%
MED ✓-22.09%
Fwd P/E
VEEV 15.28
MED ✓-18.40
Target Up.
VEEV ✓+60.13%
MED +8.70%
Op. Margin
VEEV N/A
MED N/A
Metrics last refreshed: 6/20/2026
Quick take
VEEV vs MED Stock Comparison: AI Score, Valuation, Performance and Upside
VEEV (Veeva Systems) is the publicly traded dominant cloud software provider for life sciences with commercial, clinical, regulatory, and data capabilities, while Medidata Solutions was taken private through its 2019 acquisition by Dassault Systèmes and no longer trades independently. Veeva is the primary publicly traded life sciences pure-play cloud software company.
VEEV vs MED covers life sciences cloud software with Veeva as the publicly traded market leader and Medidata as the clinical trials technology leader now operating under Dassault Systèmes' ownership.
Live analysis · updated 6/20/2026
VEEV and MED are closely matched — they split the tracked metrics evenly. MED leads on both 1-year return (-22.09%) and forward P/E (-18.40x vs 15.28x for VEEV), a relatively favorable combination of momentum and valuation. Analyst consensus implies meaningfully more upside for VEEV (+60.13%) than for MED (+8.70%).
Normalized 1Y performance
VEEV
MED
Recent returns
VEEV
MED
Analyst price targets & sentiment
VEEV · 27 analysts
STRONG BUYHOLDSTRONG SELL
Buy (1.9/5.0)
Price target range
analyst low$165.00
analyst high$350.00
analyst mean$245.48
current price$153.30
+60.1% upside to analyst mean
MED · 1 analysts
Price target range
analyst low$12.00
analyst high$12.00
analyst mean$12.00
current price$11.04
+8.7% upside to analyst mean
Who should consider this stock?
VEEV may suit investors who:
- →Want the dominant life sciences cloud software company with near-monopoly CRM positioning and growing Vault platform adoption across drug development workflows
- →Value Veeva's high switching costs and customer retention in pharmaceutical company software contracts spanning years or decades
- →See Vault expansion (regulatory, quality, safety, clinical) as a multi-year revenue growth driver as pharma replaces legacy systems
Medidata is no longer independently traded:
- →Medidata Solutions was acquired by Dassault Systèmes in 2019 and is no longer a publicly traded U.S. company
- →For clinical trials software exposure, consider Veeva (VEEV) which has an expanding clinical platform competing with Medidata
- →Dassault Systèmes (DSY) trades on Euronext Paris for investors wanting European exposure that includes Medidata's clinical trials platform
Performance & AI score
| Metric | VEEV | MED |
|---|---|---|
| AI score | 50.3 | 23.8 |
| AI rank | #454 | #3396 |
| Latest close | $153.30 | $11.04 |
| 1M return | -6.13% | -12.31% |
| 6M return | -28.85% | -9.36% |
| 1Y return | -45.53% | -22.09% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | VEEV | MED |
|---|---|---|
| 1Y ago | $5.45K (-45.5%) started 2025-06-18 | $7.79K (-22.1%) started 2025-06-18 |
| 5Y ago | $5K (-50.0%) started 2021-06-18 | $536.82 (-94.6%) started 2021-06-18 |
| 10Y ago | $44.71K (+347.1%) started 2016-06-20 | $5.92K (-40.8%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | VEEV | MED |
|---|---|---|
| Market cap | $24.9B | $122.76M |
| Trailing P/E | 27.18 | N/A |
| Forward P/E | 15.28 | -18.40 |
| Price/Sales | 7.50 | 0.35 |
| EV/Revenue | 5.82 | -0.11 |
| Analyst target | $245.48 | $12.00 |
| Target upside | +60.13% | +8.70% |
Growth, profitability & risk
| Metric | VEEV | MED |
|---|---|---|
| Revenue growth | 16.30% | -34.30% |
| Earnings growth | 14.60% | N/A |
| EPS growth | +14.60% | N/A |
| FCF margin | +37.95% | +1.27% |
| Operating margin | N/A | N/A |
| Profit margin | 28.37% | -5.79% |
| ROIC proxy | 13.93% | -9.80% |
| Return on equity | 13.93% | -9.80% |
| Dividend yield | 0.00% | 0.00% |
| Beta | 0.95 | 0.66 |
| Debt/equity | 1.41 | 8.14 |
| Current ratio | 4.74 | 4.80 |
| Quick ratio | 4.67 | 4.00 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
VEEV max drawdown50.55%
MED max drawdown37.39%
VEEV max wkly drop16.81%
MED max wkly drop11.76%
5Y risk snapshot
VEEV max drawdown55.69%
MED max drawdown96.29%
VEEV max wkly drop21.64%
MED max wkly drop29.09%
10Y risk snapshot
VEEV max drawdown55.69%
MED max drawdown96.76%
VEEV max wkly drop21.64%
MED max wkly drop31.95%
Performance metrics by period
| Period | Metric | VEEV | MED |
|---|---|---|---|
| 1Y | Growth | -45.53% | -22.09% |
| CAGR | -45.55% | -22.10% | |
| Sharpe ratio | -1.63 | -0.51 | |
| Max drawdown | 50.55% | 37.39% | |
| Max daily drop | 9.77% | 5.83% | |
| Max wkly drop | 16.81% | 11.76% | |
| 5Y | Growth | -50.02% | -95.27% |
| CAGR | -12.95% | -45.68% | |
| Sharpe ratio | -0.30 | -1.22 | |
| Max drawdown | 55.69% | 96.29% | |
| Max daily drop | 16.24% | 22.47% | |
| Max wkly drop | 21.64% | 29.09% | |
| 10Y | Growth | +347.07% | -55.92% |
| CAGR | +16.17% | -7.87% | |
| Sharpe ratio | 0.47 | -0.03 | |
| Max drawdown | 55.69% | 96.76% | |
| Max daily drop | 16.24% | 28.65% | |
| Max wkly drop | 21.64% | 31.95% |
Business comparison
| Category | VEEV | MED |
|---|---|---|
| Company | Veeva Systems Inc. | Medidata Solutions (Dassault Systèmes) |
| Sector | Technology - Life Sciences Cloud | Technology - Clinical Trials Cloud |
| Industry | N/A | N/A |
| Core business | Veeva Systems provides cloud-based software for the global life sciences industry — including CRM (Veeva CRM for pharma sales reps), regulatory (Vault platform), clinical (Veeva Clinical), and data solutions (Veeva Data Cloud) for pharmaceutical and biotech companies. | Medidata Solutions provides cloud-based clinical trials management software — including EDC (electronic data capture), RTSM (randomization and trial supply management), and patient-facing eClinical tools — acquired by Dassault Systèmes in 2019 and now operated as a division. |
| Investor focus | Investors track Veeva's commercial cloud ARR, Vault platform ARR (replacing legacy systems in clinical, quality, and regulatory), and the long-term growth trajectory as Veeva expands from CRM into the full drug development lifecycle. | Medidata is no longer a publicly traded independent company — it was acquired by Dassault Systèmes in 2019 and operates as Medidata, a Dassault Systèmes company. Investors seeking clinical trials software exposure can access it through Dassault Systèmes (DSY on Euronext Paris) or through Veeva's expanding clinical portfolio. |
VEEV strengths
- →Veeva CRM is the dominant CRM used by pharmaceutical sales representatives globally — near-monopoly positioning creates extraordinary switching costs
- →Vault platform is systematically replacing legacy document management systems across clinical, quality, regulatory, and safety departments
- →Life sciences focus provides deep domain expertise that horizontal CRM or cloud platforms lack — critical for pharma's complex regulatory environment
MED strengths
- →Medidata Rave is the most widely used electronic data capture (EDC) platform in clinical trials globally — used in trials for 95%+ of top 25 pharmaceutical companies
- →Unified clinical data platform spanning EDC, RTSM, eTMF, and patient data provides a comprehensive clinical operations solution
- →Dassault Systèmes' 3DEXPERIENCE platform integration expands Medidata's scientific design and virtual trial capabilities
Risks to watch — VEEV
- →Veeva transitioned from Salesforce platform to its own Veeva Vault CRM — this migration creates risk for some legacy Veeva-on-Salesforce customers
- →Competition from IQVIA technology solutions and increasingly from niche clinical and regulatory software vendors for specific Vault modules
- →Life sciences industry consolidation (M&A between pharma companies) can reduce the total count of independent software-buying entities
Risks to watch — MED
- →Medidata is no longer independently publicly traded — it is a division of French conglomerate Dassault Systèmes
- →Veeva has expanded its clinical platform to compete directly with Medidata for clinical data management contracts
- →Investors seeking clinical trials software exposure through public U.S. markets should consider Veeva (VEEV) for life sciences cloud exposure
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →